Delivery Order SPE2DB25D2204-SPE2DB25FTGJF
- Not listed
- The Defense Logistics Agency awarded a $1,132.95 firm fixed-price delivery order to AmerisourceBergen Drug Corp for HUMIRA (Adalimumab) Pen 40 mg/0.4 mL, a biologic medication used to treat autoimmune inflammatory conditions. The delivery order, awarded on July 31, 2025, with an ultimate completion date of August 1, 2025, was issued without a set-aside designation, indicating it was competitively awarded. Performance will be executed at AmerisourceBergen's corporate office in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 6, 2025, for the supply of HUMIRA (adalimumab) CF Pen 40 mg/0.4 mls, a biologic immunosuppressant medication used to treat inflammatory conditions. This firm fixed-price delivery order, valued at $3,776.50, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.999 billion vehicle running through December 2026. The...
- The Defense Logistics Agency awarded a $7,022.45 delivery order to AmerisourceBergen Drug Corp for HUMIRA (Adalimumab) CF Pen 40 mg/0.4 mL on July 28, 2025, with an ultimate completion date of July 29, 2025. This non-competitive delivery order is issued under a firm fixed-price arrangement and represents a single pharmaceutical supply transaction sourced from AmerisourceBergen's place of performance in Conshohocken, Pennsylvania. HUMIRA is a widely prescribed biologic immunosuppressant used to...
- The Defense Logistics Agency awarded a $4,531.80 delivery order to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mls on August 28, 2025, with an ultimate completion date of August 29, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026. The place of...
- The Defense Logistics Agency awarded a delivery order valued at $37,698.62 to AmerisourceBergen Drug Corp for the supply of HUMIRA (Adalimumab) Pen 40 mg/0.4 mL, a biologic pharmaceutical used to treat autoimmune conditions. This firm fixed-price delivery order was competitively awarded without set-aside designation and has an ultimate completion date of May 21, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency awarded a delivery order valued at $53,776.82 to AmerisourceBergen Drug Corp for HUMIRA (adalimumab) pen 40 mg/0.4 mL, a biologic medication used primarily for rheumatoid arthritis and other autoimmune conditions. This firm fixed-price delivery order, awarded on September 9, 2025, with an ultimate completion date of September 10, 2025, represents a non-competitive set-aside procurement conducted under the company's existing Indefinite Delivery Contract with DLA Troop...
- The Defense Logistics Agency awarded a delivery order valued at $9,883.59 to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mls on August 21, 2025, with an ultimate completion date of August 22, 2025. This competitively awarded, firm fixed-price contract contains no set-aside designation and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The pharmaceutical product will be delivered from...
- The Defense Logistics Agency awarded a delivery order valued at $1,529.47 to AmerisourceBergen Drug Corp for HUMIRA (adalimumab) CF Pen 40 mg/0.4 mL pharmaceutical supply. This contract, awarded on July 28, 2025, with an ultimate completion date of July 29, 2025, represents a firm fixed-price delivery order with no set-aside designation. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract issued under...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 7, 2025, for the supply of HUMIRA (adalimumab) CF Pen 40 mg/0.4 mL, a biologic immunosuppressant medication used to treat inflammatory conditions. This competitively awarded, firm fixed-price delivery order has a ceiling value of $40,270.50 and an ultimate completion date of July 8, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical...
- The Defense Logistics Agency awarded a delivery order valued at $10,983.76 to AmerisourceBergen Drug Corp for HUMIRA (Adalimumab) Pen 80 mg/0.8 mL, a biologic immunosuppressant medication used to treat autoimmune conditions including rheumatoid arthritis, Crohn's disease, and ulcerative colitis. This firm fixed-price delivery order, awarded on August 14, 2025, with an ultimate completion date of August 15, 2025, represents a routine pharmaceutical supply transaction supporting federal healthcare...
- SPE2DB25D2204Indefinite Delivery Contract
- SPE2DB25D2204-SPE2DB25FTGJFDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on April 21, 2025, for the supply of Humira (adalimumab) CF Pen 40 mg/0.4 mL, a biologic medication used to treat inflammatory conditions including rheumatoid arthritis, Crohn's disease, and ulcerative colitis. This firm fixed-price delivery order, valued at $11,476.66, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The order was competitively awarded with no set-aside designation and is scheduled for completion by April 22, 2025, with performance at AmerisourceBergen's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp serves as a critical pharmaceutical distributor for federal military and healthcare systems, leveraging its comprehensive IDC vehicle to fulfill ongoing medical supply requirements across the Defense Health Agency and other government healthcare entities. The company's role as a prime vendor under the DLA Medical Supply Chain demonstrates its capability to deliver specialized pharmaceutical products on a global scale, supporting military healthcare operations worldwide. This delivery order exemplifies the routine execution of AmerisourceBergen's broader federal pharmaceutical supply mission through individual ordering mechanisms under its existing contract authority.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $11.5k | 4/21/25 |